Congratulations to Kineticos’ Founder and CEO, Shailesh Maingi, on joining the Arranta Bio board. Arranta Bio is a human microbiome contract development and manufacturing organization.
“I am delighted to partner with Mark, the board, and the team at Arranta Bio, following his success with Brammer Bio and Gallus Biopharmaceuticals. This is an exciting time for the microbiome sector which is poised to deliver meaningful products that improve healthcare. I look forward to supporting Arranta Bio’s leading role in serving this field,” Shailesh Maingi said.
View Arranta Bio’s Press Release
About Kineticos:
Kineticos is an award-winning organization supporting Biopharmaceutical and Precision Medicine firms. Launched in 2007, Kineticos initially concentrated on strategy, licensing, and market access support for Precision Medicine firms. In 2012, Kineticos launched its Biopharmaceutical practice. In 2016, Kineticos launched its internal think tank, The Kineticos Research Institute, which includes the Biotech CEO Confidence Index, The Disruptor26 podcast series, white papers, and other relevant content. In 2019, Kineticos was selected as Life Science Consultant of the Year.
In 2020, with the launch of the Kineticos Disruptor Fund, Kineticos recognized the need for a new model to support life science start-ups integrating intelligent funding, biotech expertise, and thoughtful execution. Kineticos has a deep and talented community of advisors to support biotech formation and funding. Ongoing relationships with larger pharmaceutical and biotech companies provide our portfolio companies with numerous opportunities for research collaborations and non-dilutive funding.